Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories'
Irbesartan and Hydrochlorothiazide 300 mg / 25 mg Tablets under fed conditions